<DOC>
	<DOC>NCT02198664</DOC>
	<brief_summary>This is a multi-center, open-label, follow-on study to gather additional information on the safety and tolerability of oral desensitization with CPNA in the subjects who participated in ARC001.</brief_summary>
	<brief_title>Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using (CPNA) Peanut OIT Safety Follow-On Study</brief_title>
	<detailed_description>All subjects will receive daily oral dosing of peanut OIT (oral immunotherapy) in the form of Characterized Peanut Allergen (CPNA). Study Duration - 12-90 weeks before reaching the Extended Maintenance Phase. All Subjects may continue Extended Maintenance Phase until CPNA becomes commercially available or the study is terminated.</detailed_description>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Completion of ARC001 study Use of birth control for females of childbearing age No change in the status of any longitudinally applicable ARC001 inclusion criteria Early termination from ARC001 Failure to tolerate 300 mg of peanut protein in the ARC001 exit food challenge A lapse in dosing of more than 10 days from completion of ARC001 Change in the status of any longitudinally applicable ARC001 exclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Characterized Peanut Allergen</keyword>
	<keyword>Peanut</keyword>
	<keyword>OIT</keyword>
	<keyword>Oral Desensitization</keyword>
	<keyword>Peanut Allergen</keyword>
	<keyword>Peanut-Allergic Children</keyword>
	<keyword>Children</keyword>
	<keyword>Peanut-Allergic Adults</keyword>
</DOC>